Curis (NASDAQ:CRIS) Stock Scheduled to Reverse Split on Monday, July 6th

Posted by Stanley Muller on Jul 2nd, 2026

Curis, Inc. (NASDAQ:CRIS – Free Report) shares are set to reverse split before the market opens on Monday, July 6th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 5th.

Curis Trading Down 17.9%

Shares of NASDAQ:CRIS traded down $0.08 during mid-day trading on Thursday, reaching $0.35. The stock had a trading volume of 2,359,126 shares, compared to its average volume of 1,895,807. The firm has a market cap of $13.51 million, a PE ratio of -0.29 and a beta of 3.08. The firm has a 50 day simple moving average of $0.49 and a two-hundred day simple moving average of $0.75. Curis has a twelve month low of $0.18 and a twelve month high of $2.01.

Curis (NASDAQ:CRIS – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.92). On average, equities analysts anticipate that Curis will post -1.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CRIS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Curis in a research note on Friday, March 20th. Wall Street Zen upgraded Curis to a “hold” rating in a report on Saturday, March 28th. Finally, Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a report on Friday, May 22nd. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Curis currently has an average rating of “Reduce” and an average target price of $17.00.

Check Out Our Latest Report on Curis

Institutional Trading of Curis

Several hedge funds and other institutional investors have recently modified their holdings of CRIS. Jane Street Group LLC boosted its position in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after buying an additional 10,586 shares during the period. XTX Topco Ltd acquired a new stake in Curis in the 4th quarter valued at approximately $26,000. Focused Wealth Management Inc lifted its stake in Curis by 83.4% in the 1st quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 49,900 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Curis by 46.2% in the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 27,343 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Curis by 52.2% during the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 125,823 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

(Get Free Report)

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.